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Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD
Abstract
Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) are increasing in prevalence but lack targeted therapeutics. Although the pathological mechanisms
behind these diseases remain unclear, both ALS and FTD are characterized pathologically by aberrant
protein aggregation and inclusion formation within neurons, which correlates with neurodegeneration.
Notably, aggregation of several key proteins, including TAR DNA binding protein of 43 kDa (TDP-43),
superoxide dismutase 1 (SOD1), and tau, have been implicated in these diseases. Proteomics methods
are being increasingly applied to better understand disease-related mechanisms and to identify
biomarkers of disease, using model systems as well as human samples. Proteomics-based approaches
offer unbiased, high-throughput, and quantitative results with numerous applications for investigating
proteins of interest. Here, we review recent advances in the understanding of ALS and FTD
pathophysiology obtained using proteomics approaches, and we assess technical and experimental
limitations. We compare findings from various mass spectrometry (MS) approaches including
quantitative proteomics methods such as stable isotope labeling by amino acids in cell culture (SILAC)
and tandem mass tagging (TMT) to approaches such as label-free quantitation (LFQ) and sequential
windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) in studies of ALS and
FTD. Similarly, we describe disease-related protein-protein interaction (PPI) studies using approaches
including immunoprecipitation mass spectrometry (IP-MS) and proximity-dependent biotin identification
(BioID) and discuss future application of new techniques including proximity-dependent ascorbic acid
peroxidase labeling (APEX), and biotinylation by antibody recognition (BAR). Furthermore, we explore the
use of MS to detect post-translational modifications (PTMs), such as ubiquitination and phosphorylation,
of disease-relevant proteins in ALS and FTD. We also discuss upstream technologies that enable
enrichment of proteins of interest, highlighting the contributions of new techniques to isolate diseaserelevant protein inclusions including flow cytometric analysis of inclusions and trafficking (FloIT). These
recently developed approaches, as well as related advances yet to be applied to studies of these
neurodegenerative diseases, offer numerous opportunities for discovery of potential therapeutic targets
and biomarkers for ALS and FTD.
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Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD) are increasing in prevalence but lack targeted
therapeutics. Although the pathological mechanisms behind these diseases
remain unclear, both ALS and FTD are characterized pathologically by aberrant
protein aggregation and inclusion formation within neurons, which correlates with
neurodegeneration. Notably, aggregation of several key proteins, including TAR DNA
binding protein of 43 kDa (TDP-43), superoxide dismutase 1 (SOD1), and tau, have
been implicated in these diseases. Proteomics methods are being increasingly applied
to better understand disease-related mechanisms and to identify biomarkers of disease,
using model systems as well as human samples. Proteomics-based approaches offer
unbiased, high-throughput, and quantitative results with numerous applications for
investigating proteins of interest. Here, we review recent advances in the understanding
of ALS and FTD pathophysiology obtained using proteomics approaches, and we
assess technical and experimental limitations. We compare findings from various mass
spectrometry (MS) approaches including quantitative proteomics methods such as
stable isotope labeling by amino acids in cell culture (SILAC) and tandem mass tagging
(TMT) to approaches such as label-free quantitation (LFQ) and sequential windowed
acquisition of all theoretical fragment ion mass spectra (SWATH-MS) in studies of
ALS and FTD. Similarly, we describe disease-related protein-protein interaction (PPI)
studies using approaches including immunoprecipitation mass spectrometry (IP-MS)
and proximity-dependent biotin identification (BioID) and discuss future application
of new techniques including proximity-dependent ascorbic acid peroxidase labeling
(APEX), and biotinylation by antibody recognition (BAR). Furthermore, we explore the
use of MS to detect post-translational modifications (PTMs), such as ubiquitination
and phosphorylation, of disease-relevant proteins in ALS and FTD. We also discuss
upstream technologies that enable enrichment of proteins of interest, highlighting the
contributions of new techniques to isolate disease-relevant protein inclusions including
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flow cytometric analysis of inclusions and trafficking (FloIT). These recently developed
approaches, as well as related advances yet to be applied to studies of these
neurodegenerative diseases, offer numerous opportunities for discovery of potential
therapeutic targets and biomarkers for ALS and FTD.
Keywords: amyotrophic lateral sclerosis, frontotemporal dementia, proteomics, mass spectrometry, protein
aggregation

INTRODUCTION

Weskamp and Barmada, 2018). TDP-43 has been reproducibly
identified as one of the components of cytosolic protein
inclusions, a pathological hallmark in almost all ALS and
some FTD cases (known pathologically as frontotemporal lobar
degeneration with TDP-43 pathology, FTLD-TDP), irrespective
of genetic inheritance or mutation (Neumann et al., 2006,
2007; Wang et al., 2008). Aberrant cytoplasmic TDP-43 has
been reported in neurons and glial cells of the central nervous
system in patients with either ALS or FTD (Arai et al., 2006;
Neumann et al., 2006), and TDP-43 is therefore a primary target
for studies of mechanisms of these diseases. Indeed, mutations
in numerous other ALS-linked genes, including C9ORF72,
are also characterized by the presence of TDP-43 pathology
(Chew et al., 2015).
Although TDP-43 is the main pathological protein in almost
all ALS cases, the first known causative mutations linked to ALS
were identified in the protein SOD1 (Rosen et al., 1993), and these
account for approximately 20% of all familial ALS cases (Pasinelli
and Brown, 2006). SOD1 is a cytosolic protein responsible
for catalyzing the breakdown of harmful superoxide radicals
(Field et al., 2003; Sea et al., 2015). However, disease-causative
mutations in the SOD1 protein variably affect protein function,
and knockout of SOD1 in animals does not result in an
ALS-like disease, such that the primary mechanism of toxicity
of mutant SOD1 is considered to be a gain-of-function even if
alterations in SOD1 function may modify disease presentation
(Valentine et al., 2005; Saccon et al., 2013). Mutant SOD1 forms
large intraneuronal inclusions in people with ALS-linked SOD1
mutations as well as in cellular and animal model systems (Bruijn
et al., 1998; Kato et al., 2000; Ayers et al., 2017).
Unlike SOD1, tau is a primarily neuronal axoplasmic protein
that stabilizes microtubules (Kadavath et al., 2015). Numerous
other roles for tau have been also been described, such as
inhibition of HDAC6, a protein involved in tubulin acetylation
(Perez et al., 2009), and in intraneuronal transport (Bodea et al.,
2016). Importantly, phosphorylation of tau has been shown to
correlate with the formation of tau inclusions that are present in
tissue from people with FTD (Vega et al., 2005), and mutations
within the MAPT gene encoding tau are a prominent cause
of non-TDP-43-associated cases of FTD (Rademakers et al.,
2004). Indeed, aggregation of tau and alterations in tau function
are prominent in FTLD-tau as well as other neurodegenerative
diseases, including Alzheimer’s disease (Frost et al., 2015).
Overall, numerous mechanisms have been implicated in the
pathogenesis of these diseases, related to mutations and/or
dysfunctions which impact on neuronal viability via changes
in numerous pathways including intracellular transport, cellular
stress responses, RNA metabolism and protein clearance

Neurodegenerative diseases, including amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD),
demonstrate dysfunctional protein clearance and accumulation
of protein-rich inclusions in neuronal cells. Resolving whether
these inclusions are a cause of cellular degeneration or a
symptom of homeostatic dysfunction has proven difficult, and
the pathological mechanisms underlying their formation are still
largely unknown. However, through attempting to answer these
questions, the fundamental roles of protein aggregation and
protein clearance in the pathology of these diseases have been
established. Recent advances in proteomics technologies have
advanced our understanding of both the primary pathological
proteins as well as other associated proteins that may play
downstream roles in disease mechanisms. The purpose of this
review is to evaluate the current proteomic tools and techniques
being used to understand these diseases, to summarize the state
of knowledge gained from proteomic studies on ALS and FTD,
and to discuss development of more effective disease-modifying
treatments and biomarkers for clinical assessment driven by new
advances in proteomic technologies.

Pathology and Disease Mechanisms of
ALS and FTD
ALS and FTD are both debilitating neurodegenerative diseases
caused by selective loss of subsets of neurons. In ALS, disease
pathology primarily affects the motor neurons of the primary
motor cortex and spinal cord (Foster and Salajegheh, 2019), and
in FTD, neurons of the frontal and temporal lobe are the primary
targets of degeneration (Olney et al., 2017). Characteristic of
these neurodegenerative diseases is the accumulation of protein
inclusions in the cytoplasm of neurons (Ling et al., 2013).
These pathological proteins, which may be affected by inherited
mutations in familial disease or undergo unclear pathological
changes in sporadic cases of disease, include but are not
limited to TAR DNA binding protein of 43 kDa (TDP-43),
superoxide dismutase 1 (SOD1) and microtubule-associated
protein tau (Ling et al., 2013). Numerous mutations in these
and other proteins have been shown to individually cause either
ALS or FTD, or indeed both diseases in the same patient or
within the same family; however, the vast majority of ALS
cases and approximately half of all FTD cases have no known
underlying dominant mechanism of inheritance (Ling et al., 2013;
Nguyen et al., 2018).
Prominent amongst these pathological proteins is TDP-43,
which is a highly conserved predominantly nuclear protein
with functional roles in RNA metabolism (Ayala et al., 2008;
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Impairment of proteasomal degradation likely also contributes
to the accumulation of ubiquitinated proteins, including SOD1
and TDP-43 (Cheroni et al., 2005, 2009; Scotter et al., 2014).
Numerous factors, such as activation of cellular stress responses
and dysfunctions in proteasome activity and autophagy, may
contribute to varying degrees to the accumulation of proteins
in disease, although the underlying mechanisms of inclusion
formation and associated pathophysiology remain unclear
(Tanaka and Matsuda, 2014). However, since protein aggregation
and inclusion formation are hallmarks of these diseases,
understanding these processes, and how protein aggregation
perturbs neuronal function, is likely to reveal new ways to delay
or prevent neurodegeneration.
Proteins that are supersaturated, meaning that their
concentration in the cell is greater than their predicted
solubility, also have a higher propensity to aggregate (Ciryam
et al., 2017). In ALS and FTD, proteins such as TDP-43 have
been shown to be supersaturated due to their unusually high
concentration (Ciryam et al., 2017). Phase transitions may result
in proteins precipitating out in the cytoplasm, a liquid-liquid
separation, and proteins with low complexity domains such as
TDP-43 may be more prone to this transition (Li et al., 2018).
Indeed, recently RNA has been proposed as a regulator of
protein phase separation, suggesting that dysregulation of RNA:
protein interactions may contribute to the formation of protein
aggregates (Maharana et al., 2018; Zacco et al., 2019).
Analyzing how disease-related proteins aggregate,
identification of the interaction partners of native and
aggregated pathological proteins, and determination of the
consequences of protein aggregation within neurons will
likely elucidate the patho-mechanisms involved in ALS and
FTD. The remainder of this review will focus on the methods
and outcomes of previous and potential future studies using
proteomics technologies to address these fundamental issues. By
developing an understanding of the numerous tools available
for these experiments and devising the most relevant biological
questions, these studies offer the potential to elucidate the
mechanisms of pathogenesis of ALS/FTD, and to identify
biomarkers for these diseases. Together, this information may
allow the future development of better treatments for people
living with ALS and FTD.

machinery (Walker and Atkin, 2011; Ling et al., 2013; Zhang
et al., 2015; Tank et al., 2018). However, despite the diversity
of possible upstream causes of disease, the prominence of
protein aggregation suggests that this plays a key role in driving
neurodegeneration in ALS and FTD.

Proteostasis and Protein Aggregation in
ALS and FTD
Proteins are the functional components that drive the majority
of cellular processes. Protein homeostasis or “proteostasis”
describes a network of constitutively expressed housekeeping
and cellular stress-inducible molecular pathways that maintain
proteins in a biologically active conformation, or degrade
them, to ensure that cell viability is not compromised (Balch
et al., 2008; Hipp et al., 2014). The proteostasis network can
be clustered into several pathways including the heat shock
response, unfolded protein response, ubiquitin-proteasome
system (UPS), and autophagy machinery (Webster et al.,
2017). Under physiological conditions, the mechanisms of
proteostasis function sufficiently to maintain cell viability.
However, if proteostasis deteriorates or becomes overwhelmed,
for example in the context of ALS and FTD, aberrant protein
accumulation and aggregation can occur, and cell viability
may be threatened.
Under normal cellular conditions, proteins exist in their
native conformation, consisting of external hydrophilic surfaces
and an internal hydrophobic core. Apart from the folding that
occurs for nascent polypeptides as they are synthesized on
the ribosome, protein folding and unfolding occurs at other
important times during the lifespan of many proteins. For
example, proteins unfold and are refolded during trafficking
across intracellular membranes, cellular secretion, and during
times of cellular stress (Kincaid and Cooper, 2007; Gregersen
and Bross, 2010). When proteins are subjected to cellular stresses,
such as oxidative stress or increased burden to mitochondria or
the endoplasmic reticulum, they may unfold and form partially
folded protein intermediates that expose the hydrophobic regions
of the polypeptide to the cytosol, which are otherwise buried
within the protein (Hipp et al., 2014). Exposed hydrophobic
regions are attracted to similar hydrophobic regions on adjacent
partially folded protein intermediates, which may aggregate
together and enter thermodynamically favorable pathways that
lead to the formation of higher-order oligomers (Stefani, 2008).
These oligomers may be toxic and also form the building blocks
of larger aggregates and protein inclusions in neurodegenerative
diseases (Lasagna-Reeves et al., 2012; Blair et al., 2013; AitBouziad et al., 2017; Shafiei et al., 2017).
The maintenance of functional proteostasis to ameliorate
protein aggregation is particularly important in post-mitotic
cells such as neurons, since disrupted proteostasis cannot be
simply counteracted by apoptosis and replacement with new
healthy neurons, unlike most other cell types (Morimoto, 2008).
A recent review has discussed evidence that cellular stress in
the spinal cord of the SOD1G93A mouse, the most widely
used model of ALS, does not result in the induction of the
anti-aggregation heat shock response, which may suggest that
this pathway is impaired in disease (San Gil et al., 2017).
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PROTEOMIC APPROACHES TO STUDY
ALS AND FTD
Proteomic-based platforms are becoming increasingly
powerful to identify both potential disease mechanisms
as well as disease biomarkers. Proteomics involves using
highly complex protein screening technology for biological
understanding on a wide-scale level. This information can
then be used in combination with genomic data to provide
an understanding of the fundamental biological mechanisms
underlying neurodegenerative diseases. The emergence of
newer sophisticated mass spectrometry (MS) technology in the
past decade, with higher resolution and faster scan rates, has
enabled smoother and quicker identification of highly complex
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where they can be fragmented (MS/MS) further for peptide
identification. The data generated by MS can be searched
using algorithms that incorporate protein databases to
generate lists of identified proteins. The two major streams
for quantitative proteomics that are widely used are labelfree and labeled quantitation (Figure 1). Both methods
are used for the identification and quantitation of protein
components between altered physiological states such as

proteomes with shorter analysis periods (Chapman et al., 2014).
The typical sample preparation procedures for proteomics
analysis involves digesting proteins into peptides using a
protease (e.g., trypsin and/or Lys-C) followed by reverse
phase C18 liquid chromatographic separation and analysis
by mass spectrometry (LC-MS/MS) (Tholey and Becker,
2017). The peptides that are eluted from the C18 column
are directly ionized into the mass spectrometer for analysis,

FIGURE 1 | Proteomics workflow for label-free and labeling quantitation of proteins from complex mixtures relevant to understanding ALS and FTD. Protein samples
derived from models/human tissue can either be labeled for targeted proteomics or analyzed label-free for broader detection. DDA, data-dependent acquisition; DIA,
data-independent acquisition; and SILAC, stable isotope labeling by amino acids in cell culture.

Frontiers in Neuroscience | www.frontiersin.org

4

June 2019 | Volume 13 | Article 548

Hedl et al.

Proteomics for ALS and FTD

the dysfunctional similarities between these diseases (Iridoy
et al., 2018). Similar analysis of brain tissues has provided
insight into the various subtypes of ALS and FTD, distinguishing
between them by highlighting differences in levels of numerous
proteins as well as differences in protein aggregate assembly,
distribution and morphology (Umoh et al., 2018; Laferriere et al.,
2019). A sequential biochemical extraction technique to purify
detergent-insoluble aggregated proteins resulted in enrichment
of phosphorylated TDP-43 and identification of low-solubility
proteins associated with TDP-43 pathology (Laferriere et al.,
2019). Subsequent MS of these enriched proteins determined
distinct patterns of enrichment amongst ALS (23 proteins) and
subtypes of FTLD (FTLD-A: 8 proteins; FTLD-C: 10 proteins),
providing insights into potential causes of disease heterogeneity
(Laferriere et al., 2019). A summary of studies to investigate the
mechanisms of ALS and FTD that have used human brain and
spinal cord samples for LFQ are presented in Table 1.
LFQ proteomics has also been applied to animal models,
for example identifying interactors of misfolded SOD1 in the
spinal cord of SOD1G93A mice over three pre-symptomatic time
points in disease (Ruegsegger et al., 2016). Only 5 identified

those in ALS and FTD, to differentiate their cellular and
molecular mechanisms.

Label-Free Quantitation Proteomics
Studies of ALS and FTD
Label-free quantitation (LFQ) can use either data-dependent or
data-independent acquisition (DIA) analyses. Data-dependent
acquisition quantitation can be performed on either spectral
counts or spectrometric signal intensity of product ions from
selected precursors generated by the mass spectrometer (Yu F.
et al., 2016). Recently, LFQ has been more frequently adopted
for biomarker discovery studies since it is less expensive than
labeled methods and allows comparative analysis of large groups
of samples. A comprehensive review of the technical aspects of
label-free quantitative proteomic approaches is available (Neilson
et al., 2011). LFQ proteomics can also be used as an unbiased
approach to characterize changes to a human proteome at a
pathway level. As an example, amongst the identification of
hundreds of proteins, overlapping mitochondrial and metabolic
pathway alterations have been identified from samples of both
human ALS and FTD brain and spinal cord samples, highlighting

TABLE 1 | Human tissue proteomics studies using label-free techniques for mechanistic insight into ALS and FTD.
Sample

Summary

Remarks

References

ALS (TDP-43+) and FTLD-TDP
brain

Isolation of phosphorylated TDP-43
with numerous other insoluble proteins,
which differentiate ALS and FTLD-TDP
subtypes

TDP-43 proteinopathy variation may
stem from alternate pathological
TDP-43 conformations

Laferriere et al., 2019

ALS (TDP-43+) and FTLD-TDP
spinal cord and frontal cortex

281 proteins ↑/↓ in ALS and 52 ↑/↓ in
FTLD-TDP (33 proteins overlap)

ALS and FTD share molecular
alterations including mitochondrial and
metabolic impairment

Iridoy et al., 2018

ALS and FTLD-TDP brain

Identified 15 modules of co-regulated
proteins (8 significantly different across
subtypes of ALS and FTLD-TDP)

Subtypes of FTLD-TDP and ALS
differentiated by insoluble protein
proteomic signature, possibly reflecting
common/differing mechanisms

Umoh et al., 2018

ALS brain

Phosphorylation, deamidation and
cleavage sites of TDP-43 almost all in
the glycine-rich C-terminus

Modifications of TDP-43 may affect
molecular pathways in disease

Kametani et al., 2016

ALS frontal cortex

Fungal antigens in human ALS brain
within cytoplasmic structures

Fungal infection may occur in ALS

Alonso et al., 2015

ALS spinal cord

Altered detergent-insoluble protein
acetylation, including GFAP, in ALS

Dysregulation of protein acetylation may
be involved in ALS pathology

Liu et al., 2013

FTD frontal cortex

↓ C9ORF72 long protein isoform in
disease

Novel method for quantifying C9ORF72
isoforms

Viode et al., 2018

FTLD-TDP brain

↑/↓ 50 proteins FTLD-TDP, including
TDP-43 and septin 11

Identified and characterized enriched
proteins in the detergent-insoluble
fraction

Gozal et al., 2011b

FTLD-TDP hippocampus

↑ 54 proteins (including TDP-43) and ↓
19 proteins in FTLD-TDP laser-captured
dentate gyrus neurons

Potential pathology-associated proteins
identified

Gozal et al., 2011a

FTD, PiD, CBD, intronic tau
mutation and PSP brain

C-terminus of tau is protease-resistant,
cleavage pattern may differentiate
subtypes of FTD and AD

Analysis of tau C-terminus in FTD
potentially useful in classifying disease
subtypes

Taniguchi-Watanabe et al., 2016

sALS spinal cord

21 proteins ↑/↓, ↑ mitochondrial
metabolism proteins, ↓ ATP5D and
calmodulin

Synaptic mitochondrial changes
potentially involved in ALS

Engelen-Lee et al., 2017

↑ denotes increase; ↓ denotes decrease; AD, Alzheimer’s disease; ATP5D, mitochondrial membrane ATP synthase; CBD, corticobasal degeneration; FTD, frontotemporal
dementia; FTLD, frontotemporal lobar degeneration; GFAP, glial fibrillary acidic protein; PiD, Pick’s disease; PSP, progressive supranuclear palsy; sALS, sporadic
amyotrophic lateral sclerosis; and TDP-43, TAR DNA binding protein of 43 kDa.
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(Hogan et al., 2017). Studies such as these that combine analysis
of different models, such as cells and in vivo systems, using
both proteomics and complementary validation approaches offer
the best approach to identify biologically relevant changes.
The selection of proteins for validation is often based on the
statistically significant findings from the proteomic analysis as
well as previously published work in the literature, however,
pathway-level approaches for analysis of large datasets are often
more informative than extensive analysis of individual proteins.
A summary of ALS and FTD studies that have used animal
models for LFQ are presented in Table 2.
The majority of the previous investigative studies have used
heterogeneous samples, which poses a limitation. Rather than
representing proteomes from only a specific cell type of interest,
they largely consist of populations of homogenized and variable
cell types. To account for this, reemergence of laser-capture

proteins were common across these groups with high confidence,
including HSPA8. The bulk of proteins found to interact
with misfolded SOD1 were identified at the latest time point
(Ruegsegger et al., 2016). Of all mutant SOD1 interactors,
the activity of Na+ /K+ ATPase-α3 was decreased and exhibited
higher levels of protein expression in high-vulnerability motor
neurons (Ruegsegger et al., 2016).
Mutations in cyclin F (CCNF S621G ), which cause rare familial
cases of ALS/FTD, have also been studied by overexpression in
neuronal cell lines and zebrafish to investigate the effects and
mechanisms of ALS/FTD (Williams et al., 2016; Hogan et al.,
2017; Lee A. et al., 2018). Hundreds of proteins were increased
or decreased upon expression of disease-linked mutant cyclin F
protein (Lee A. et al., 2018). The differentially expressed proteins
clustered to cell pathways involved with cellular survival and
toxicity, and predicted activation of caspase-3 mediated cell death

TABLE 2 | Animal model proteomics studies using label-free techniques for mechanistic insight into ALS and FTD.
Sample

Summary

Remarks

References

Grn−/− , TMEM106B−/−
mouse brain

↑ 17 and ↓ 2 lysosomal proteins with Grn−/− ,
phenotype normalized by Tmem106b−/−

Alterations in lysosomal function may contribute
to risk of FTD

Klein et al., 2017

Non-transgenic mouse cortex

IP-MS of TDP-43 suggests interactions with
mitochondrial proteins, including PHB2

Normal function of TDP-43 may be related to
mitochondria

Davis et al., 2018

rTg4510 tau mice (P301L
4R0N) brain

↑ nucleotide-binding proteins ↓ RNA binding
and ribonucleoproteins in tauopathy

Identified proteins that co-localize with tau
inclusions and changes in expression

Maziuk et al., 2018

SOD1G93A mouse brain and
spinal cord EVs

Only 1 protein ↑/↓ in SOD1G93A EVs (↓ MOG)

EVs may originate from astrocytes and contain
RBPs, but little change in disease

Silverman et al., 2019

SOD1G93A mouse muscle
tissue

ER stress response is activated in skeletal
muscle of SOD1 mice ↑ CHOP, BiP and PERK

ER stress leads to reduced protein translation,
involvement in muscle atrophy and weakness
seen in ALS

Chen et al., 2015

SOD1G93A mouse spinal cord

↓ VGF peptides, similar findings in ALS plasma

Selective depletion of VGF fragments may be
involved in disease etiology

Brancia et al., 2016

SOD1G93A mouse spinal cord

67 ↑/↓ lipid raft proteins, involved in vesicular
transport, neurotransmitter synthesis/release,
cytoskeletal organization and metabolism

Lipid raft protein changes in ALS may affect
vesicular trafficking, neurotransmitter signaling
and cytoskeleton

Zhai et al., 2009

SOD1G93A mouse ventral horn
spinal cord

IP-MS of interactors of misfolded SOD1 (three
time points), primarily chaperones, transporters
and hydrolases (notably HSPA8,
Na+ /K+ ATPase-α3)

Na+ /K+ ATPase-α3 levels are high in vulnerable
MNs, and expression may modulate disease
pathology and phenotype

Ruegsegger et al., 2016

SOD1G93A rat spinal cord
mitochondria

↑ 33 proteins and ↓ 21 proteins, mostly
involved in complex I and mitochondrial protein
import

Mitochondrial protein alterations and ↓ protein
import may contribute to mutant
SOD1-associated mitochondrial deficits

Li et al., 2010

SOD1WT or G93A or G85R mouse
spinal cord

Enriched detergent-insoluble proteins, including
VILIP-1

VILIP-1 may affect oxidation status and calcium
levels in ALS

Liebl et al., 2014

Squid axoplasm combined with
SOD1G85R protein

Addition of HSP110 to mutant SOD1 affected
axoplasm rescued the transport defect and
phosphorylation of p38 seen in pathology

Highlights potential of HSP110 in association
with HSC70 as a mediator of protein
disaggregation for mutant SOD1 in ALS

Song et al., 2013

Synaptoneurosomes from rat
brain

IP-MS of Chmp2b complexes, identifying
association with ESCRT-III and post-synaptic
proteins

Chmp2b is part of a stable complex that
regulates synaptic plasticity, potentially relevant
to FTD mechanisms

Chassefeyre et al., 2015

Znf179−/− mouse
hippocampus

IP-MS of Znf179/RNF112 identifies interaction
with TDP-43, TDP-43 is polyubiquitinated by E3
ligase function of RNF112

↑ ubiquitination of TDP-43 ↑ degradation, loss
of RNF112 in ALS may cause TDP-43
aggregation and pathology

Lee Y.C. et al., 2018

↑, denotes increase; ↓, denotes decrease; ALS, amyotrophic lateral sclerosis; BiP, Endoplasmic reticulum chaperone BiP; CacyBP, calcyclin-binding protein; Chmp2b,
charged multivescular body protein 2b; CHOP, DNA-damage-inducible transcript/CCAAT/enhancer-binding protein; ER, endoplasmic reticulum; ESCRT-III, endosomal
sorting complex required for transport; EVs, extracellular vesicles; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; HSC70, heat shock cognate
71 kDa; HSP110, heat shock protein 110; IP-MS, immunoprecipitation mass spectrometry; KO, knockout; MFN2, mitofusin 2; PERK, PKR-like endoplasmic reticulum
kinase; PGRN, progranulin; PHB2, prohibitin 2; PMPCA, mitochondrial-processing peptidase subunit alpha; RBPs, RNA-binding proteins; RNF112/ZNF179, RING finger
protein 112; SOD1, superoxide dismutase 1; TDP-43, TAR DNA binding protein of 43 kDa; TMEM106B, transmembrane protein 106B; VGF, neurosecretory protein VGF;
and VILIP-1, Visinin-like protein 1.
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Matrix-assisted laser desorption ionization (MALDI) is
an alternative method to introduce a sample into a MS.
This differs from electro-spray ionization (ESI) through
focusing laser energy at a matrix-embedded sample for low
fragmentation and reduced multi-charged ion states (Nadler
et al., 2017). Typically ESI dominates the literature as the
intermediate in LC-MS, used in all the studies presented in
Tables 1–3. There are limitations to each technique, which
are discussed elsewhere (Nadler et al., 2017), and the choice
of technique generally depends on the biological question.
For example, in ALS and FTD studies, MALDI-MS has been
successfully applied to identify increased levels of ubiquitin
carboxy-terminal hydrolase L1 (UCHL1) in FTLD-tau cortex
(Schweitzer et al., 2006) as well as increased carbonylation
of UCHL1 in the spinal cord of SOD1 mice (Poon et al.,
2005). Together these findings have highlighted the roles
of the oxidative stress response and ubiquitin-mediated
degradation in ALS and FTD. MALDI-MS has also been
used to identify increased levels of proprotein convertase 1
inhibitor (ProSAAS) in FTD CSF (Davidsson et al., 2002)
and potentially pathologically involved ProSAAS N-terminal
fragments in the temporal lobe of FTD samples (Kikuchi
et al., 2003). More recently, MALDI-MS has been used to
identify interactions between Staufen1 and dynein, mediated
via protein phosphatase 1-beta, implicating a role of Staufen1
in regulating mRNA localization in ALS (Gershoni-Emek
et al., 2016). This has been reinforced through a described link
between Staufen1 RNA stress granules and autophagy through
interaction with ataxin-2 (Paul et al., 2018). A summary
of ALS and FTD studies that have used MALDI-MS is
presented in Table 4.

microdissection of tissues has been used to isolate distinct
cell-types, and with recent advances in MS technologies this can
now be successfully applied to proteomics studies of neurons
from brain samples (Aring et al., 2018). Newer technology that is
highly sensitive and specific can thus generate a greater number
of protein hits from small amounts of extracted sample, and this
offers opportunities for future studies of both model systems and
human ALS and FTD samples.
In addition to studies of tissue samples, much proteomics
research has been applied to understand ALS and FTD
pathogenesis using cell culture models. This approach, which
usually makes use of homogenous populations of cells such
as immortalized cell lines, removes the confound of studying
mixed samples that is often inherent using tissue samples and
biofluids. Expression of disease-associated proteins, including
mutant SOD1, TDP-43, and tau, recapitulate some features of
disease in cell models, such as protein aggregation, inclusion
formation and cellular toxicity (Gauthier-Kemper et al., 2011;
Cohen et al., 2015; Celona et al., 2017; Monahan et al., 2017;
Wang et al., 2017). Proteomics studies of these models have been
used to identify proteins that co-aggregate or interact with the
known pathological proteins, which may provide insight into
disease pathogenesis. Identification of proteins associated with
disease pathology may also help reveal proteins of potential
therapeutic use if, for example, those proteins are able to
modulate protein aggregation or toxicity (Celona et al., 2017;
Mallik et al., 2018). A summary of ALS and FTD studies that have
used cell models for LFQ are presented in Table 3.
The main limitations of LFQ using data-dependent
acquisition is the generally low proteome coverage and low
sensitivity, since many low intensity ions (often from low
abundance proteins or poorly ionized peptides) are missed
in precursor ion selection. In order to improve this coverage,
additional sample prefractionation steps (such as strong cation
exchange or basic reverse phase chromatography) can be
used to reduce the complexity of the sample to be analyzed
by MS. A recent LFQ approach that is being more widely
adopted relies on data independent quantitation with methods
such as Sequential Window Acquisition of all Theoretical
Mass Spectra (SWATH) that attempt to circumvent some of
these issues associated with analyzing complex samples by
data-dependent acquisition.
SWATH, or data-independent acquisition (DIA), acquires
data by cycling through predefined sequential windows of a
chromatographic elution range generating a larger number of
identified proteins from a complex mixture (Gillet et al., 2012).
Recently, SWATH has been used to identify differences in blood
samples between 42 ALS patients and 18 healthy controls, which
revealed a panel of novel potential biomarkers for diagnosis and
use in clinical trials (Xu et al., 2018). This study found significant
differences in the expression of 30 proteins that varied in ALS
patients with or without cognitive impairments. This study
highlights the potential of DIA methodologies, such as SWATH,
to discover markers in biofluids that may have further utility for
clinical use that offers promise to provide further advances in ALS
and FTD studies. A comprehensive review of the technical aspects
of SWATH is discussed elsewhere (Ludwig et al., 2018).
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Quantitation via Labeling Proteomics
Approaches for ALS and FTD
Labeled-based approaches have considerably higher quantitation
accuracy in exchange for lower proteome coverage compared
to LFQ (Megger et al., 2014). The labeling techniques
involve the introduction of stable isotope labels on the
proteins or peptides, which allow the mass spectrometer
to distinguish between identical peptides from different
samples within a mixture. Quantitative labeling methods
can also be used for protein-protein interactions (PPIs)
and post-translational modifications (PTM) analyses
which are discussed below (Sullivan et al., 2016; Russell
et al., 2017). A comprehensive review of the technical
aspects of labeled-based proteomic approaches is available
(Lindemann et al., 2017).

Stable Isotope Labeling by Amino Acids in Cell
Culture (SILAC)
Stable Isotope Labeling by Amino acids in Cell culture
(SILAC) labeling is achieved by growing cells in culture
with growth medium containing different isotopically labeled
amino acids that are incorporated during protein synthesis
(Ong et al., 2002). The protein lysates from different isotopelabeled cell culture are pooled together in equal amounts
and prepared as one grouped sample to decrease sample
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TABLE 3 | Cell and in vitro model proteomics studies using label-free techniques for mechanistic insight into ALS and FTD.
Sample

Summary

Remarks

References

Differentiated C2C12 mouse
myoblasts

Detected muscle specific kinase activation via
phosphorylation, which preserves innervation of
neuromuscular junctions

Innervation of neuromuscular junctions
insufficient, however, could potentially be used
as an adjuvant therapy

Sengupta-Ghosh et al., 2019

HEK239T cells and rat primary
cortical neurons infected with
GR149 or PR175

Poly-GR/PR interactome identified RNA-binding
proteins (many low-complexity domains),
cytoplasmic/mitochondrial ribosomes
components, stress granules and splicing
factors

Sequestration of ribosomes via interactions with
poly-GR/PRs would potentially impair protein
translation in FTD pathology

Hartmann et al., 2018

HEK293 and N2A cells
transfected with cyclin
FWT or S621G

Identified 7 phosphorylation sites on cyclin F

Cyclin F S621 phosphorylation by CK2
regulates Lys48-specific E3 ligase activity

Lee A. et al., 2017

HEK293 cells expressing
RBM45

Identified 132 protein-protein interactors of
RBM45

RBM45 associates with enriched proteins
involved in nuclear RNA processing: TDP-43,
Matrin-3, hnRNP-A1 and FUS

Li et al., 2016

HEK293A cells expressing
TDP-431NLS and 2KQ and CBP

Identified TDP-43 acetylation sites K145/192

TDP-43 modulation via acetylation could
potentially be used therapeutically

Cohen et al., 2015

HEK293E cells expressing
TDP-43192−414 or 1NLS or WT

Removal of 4 lysine ubiquitination sites in CTF
TDP-43 = ubiquitination suppression

Indicates interplay between ubiquitination and
phosphorylation of TDP-43 in ALS and FTD
pathology

Hans et al., 2018

HEK293T and H4 cells treated
with various drugs

Identified 28 phosphorylation sites within FUS’s
prion-like domain, following DNA-damaging
stress

Multiphosphorylation of these sites does not
cause cytoplasmic localization

Rhoads et al., 2018

HEK293T cells expressing
C9ORF72 DPRs

Interactome of DPRs: RNA-binding proteins
and proteins with low complexity sequence
domains

DPRs altered phase separation of low
complexity domain proteins, suggesting
possible mechanism involved in pathogenesis

Lee et al., 2016

HEK293T cells expressing
FUSP525L

Mutant FUS ↓ interactions with many metabolic
enzymes. Novel interactions between FUS and
VCP, PSF, UBA1 and PSMD12. FUS
accumulation = ↓ ATP levels and ↑
poly-ubiquitinated proteins

Defective energy metabolism and protein
degradation arise as a result of FUS
accumulating and interacting with key
regulators

Wang et al., 2015

HEK293T cells expressing
FUSR521G or P525L

FUS interacting proteins = fALS implicated
proteins hnRNPA1 and Matrin-3

Potential common pathogenic roles between
FUS-ALS and fALS. FUS present in exosomes
suggesting contribution to cell-to-cell
transmission/spread. Interactors also
sequestered into inclusions

Kamelgarn et al., 2016

HEK293T cells expressing
mPGRN-HA

PGRN interacts with a network of ER
chaperones such as BiP, calreticulin, GRP94
and PDI family proteins

PGRN is a substrate of several PDI proteins
and ER chaperone network control could be a
therapeutic target

Almeida et al., 2011

HEK293T cells transfected with
Zfp106

Zfp106 interacts with hexanucleotide repeat
(GGGGCC) RNA-binding protein, other
RNA-binding proteins: TDP-43 and FUS.
Zfp106 KO mice develop motor neuron
degeneration. Zfp106 suppresses neurotoxicity
in Drosophila C9orf72 ALS model

Importance and role of Zfp106 in ALS
pathology

Celona et al., 2017

HEK293T cells treated with
various drugs

Identified 17 phosphorylation sites within FUS
low-complexity domain

Phosphorylated/phosphomimetic FUS reduces
aggregation, propensity to aggregate,
ameliorates cytotoxicity and disrupt phase
separation

Monahan et al., 2017

HEL293FT cells expressing
C9ORF72 DPRs

Co-aggregators of poly-GA = Unc119, soluble
Unc119 ↓ in poly-GA expressing neurons

Loss of function of Unc119 in neurons with
DPR-type pathology as seen in C9orf72
ALS/FTD

May et al., 2014

HeLa cells expressing
C9ORF72 DPRs

Arginine-rich DPRs undergo liquid-liquid phase
separation and induce this effect on proteins
involved in RNA and stress granule metabolism

Arginine-rich DPRs derived from C9ORF72
repeat expansions play an important role in the
pathogenesis of ALS/FTD

Boeynaems et al., 2017

HeLa cells expressing FUS

FUS forms liquid-like compartments under
stress that are crucial for its role in ALS

Propensity for aggregation vs functionality of
FUS action in liquid-compartments found in
disease

Patel et al., 2015

In vitro (PGRN)

Cathepsin L cleaves intracellular PGRN

Cathepsin L identified as a key intracellular
lysosomal protease, therefore demonstrating
link between lysosomal dysfunction and FTLD

Lee C.W. et al., 2017

(Continued)
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TABLE 3 | Continued
Sample

Summary

Remarks

References

In vitro (SOD1)

SOD1G37R did not have the same propensity to
aggregate as SOD1G93A and SOD1V148G ,
however, still formed oligomeric aggregates

Slow disease progression in SOD1G37R patients
is due to structural limitations associated with
the arginine substitution at residue 37

McAlary et al., 2016

In vitro (SOD1)

Naringin is a strong native interactor of SOD1,
demonstrated to stabilize SOD1 dimers and
inhibit aggregation

Analytical method for studying interactions
between proteins and drug-like molecules,
identifying role of naringin

Zhuang et al., 2016

In vitro (tau)

K225,240,257,311,383 residues in tau involved
in crosslinking to K336,338 in α-tubulin

Identified how tau stabilizes microtubules
through identifying sites of interface

Kadavath et al., 2015

iPSC-derived motor neurons
expressing C9ORF72 DPRs
and Drosophila brain

Arginine DPRs interact with ribosomal proteins,
expression of eIF1 A rescued DPR-induced
toxicity

Repression of protein translation is involved in
C9orf72 hexanucleotide-repeat induced
neurodegeneration

Moens et al., 2019

Mouse primary hippocampal
neurons expressing scrambled
shRNA FUS

Identified PSD-95 interacting proteins: ↓
SynGAP with FUS depletion. FUS, ELAV1 and
ELAV4 exert a level of control on SynGAP
mRNA stability

FUS depleted dendritic spines associated with
internalization of PSD-95

Yokoi et al., 2017

N2a cells expressing C9ORF72

Interactors of C9ORF72 = UBQLN2,
hnRNPA2/B1, hnRNPA1 and actin.
Colocalization with RAB7 and RAB11 suggests
dysregulation of trafficking

Demonstrates the role of C9ORF72 in
RAB-mediated trafficking

Farg et al., 2014

N2a cells expressing TDP-43
and CTF

Interactome of TDP-43 using BioID identified
254 proteins vs 389 in CTF, many involved in
mRNA processing

TDP-43 aggregate associates were involved in
nuclear pore complex and transport machinery

Chou et al., 2018

NSC-34 cells expressing
C9ORF72 DPRs

Poly-PR peptides interact with mRNA-binding
proteins, ribosomal proteins, translation
initiation and elongation factors

Alterations via DPRs are potential therapeutic
targets and are involved in neurotoxicity

Kanekura et al., 2016

PC12 cells expressing
SOD1G93A

PSMC1, PSMC4 and TCP-1 activated by
pyrazolones in the absence of exogenous
proteasome inhibitor

In the absence of the heat shock response,
pyrazolones enhance proteasomal activation
and could be a potential therapeutic target

Trippier et al., 2014

S2 cells expressing
Xrp1Short or Long and
actin5C-GAL4

↑ Xrp1 expression in caz mutants, interactors
are involved in gene expression regulation

Caz is the ortholog of human FET proteins FUS,
EWSR1, and TAF15, all of which implicated in
ALS and FTD, dysregulation of gene repair
implicated

Mallik et al., 2018

SH-SY5Y cells knockdown
TDP-43

↓ RanBP1, Dnmt3a and CgB in TDP-43
knockdown. ↓ RanBP1 = ↑ transportin 1

TDP-43 mediates RNA metabolism and
intracellular transport

Stalekar et al., 2015

SKNBE2 cells expressing tau

AnxA2 interacts with tauWT but not mutant
tauR406W

TauR406W mechanism involves impaired
membrane binding due to functional interaction
with AnxA2

Gauthier-Kemper et al., 2011

SOD1 isolated from yeast

Low molecular weight fractionated SOD1 does
not appear to be post-translational modified
compared to high molecular weight SOD1,
which is oxidized at residues C146 and H71

Crucial for SOD1 structure, suggesting a role of
oxidative damage for protein misfolding

Martins and English, 2014

SOD1WT or G37R or L38V or G41D or
G93A or G93S or D101N isolated
from yeast

Structure of SOD1 amyloid fibrils and mutants
demonstrated that fibrils protected the
N-terminus from digestion via proteases

SOD1 and mutants fibrillate through the
N-terminal fragment, highlighting potential ALS
implications

Chan et al., 2013

↑, denotes increase; ↓, denotes decrease; AnxA2, Annexin A2; caz, RNA-binding protein cabeza; CgB, chorionic gonadotropin beta; CK2, casein kinase II subunit
alpha; CTF, C-terminal fragment; Dnmt3a, DNA (cytosine-5)-methyltransferase 3A; DPR, dipeptide repeat; EIF1A, eukaryotic translation initiation factor 1A; ELAV1/4,
embryonic lethal abnormal vision protein 1/4; EWSR1, RNA-binding protein EWS; FUS, fused-in-sarcoma; GFAP, glial fibrillary acidic protein; GR, glycine arginine;
GRP94, 94 kDa glucose regulated protein; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; iPSC, induced pluripotent stem cell; MTO, methanethiol oxidase;
PDI, protein disulphide isomerase; PIN1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1; PR, proline arginine; PSD-95, post-synaptic density protein 95; PSF,
polypyrimidine tract-binding protein-associated-splicing factor; PSMC1/4, 26S proteasome regulatory subunit 1/4; PSMD12, 26S proteasome non-ATPase regulatory
subunit 12; RAB7/11, Ras-related protein Rab-7/11; RanBP1, Ran-binding protein 1; RBM45, RNA binding motif protein 45; ROCK2, rho-associated protein kinase 2;
SOD1, superoxide dismutase 1; SynGAP, Ras/Rap GTPase-activating protein SynGAP; TAG15, TATA binding associated factor 15; TCP-1, T-complex protein 1; TDP-43,
TAR DNA-binding protein of 43 kDa; UBA1, ubiquitin-like modifier-activating enzyme 1; UBQLN2, ubiquilin-2; Unc119, protein unc-119 homolog A; VCP, vasolin-containing
protein; and Zfp106, zinc finger protein 106.

preparation variability. High resolution mass spectrometers
can analyze and resolve the different precursor (peptide) ions
within an experiment and detect the signal intensities of the
labeled peptides. The intensities of the precursor ions are
used as a measure of the relative abundance of the protein

Frontiers in Neuroscience | www.frontiersin.org

within each sample. One limitation of SILAC, however, is the
relatively small number of labeled amino acid combinations
[maximum reported to date is 6-plex (Wang et al., 2013)]
that can be used in one experiment, which limits the
number of comparisons.
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The versatility of SILAC can extend to the generation of
an internal standard in a cell-line to quantify low abundance
proteins in tissue (known as “Super SILAC”). This was applied
to investigate the accumulated proteins in detergent-insoluble
brain lysates from four control and four FTLD brain samples,
with comparison to a HEK293 standard (Seyfried et al., 2012).
A summary of ALS and FTD studies that have used SILAC is
presented with other labeled methods in Table 5.

Tandem Mass Tags (TMT)
Unlike SILAC, which incorporates isotopically labeled amino
acids at the protein level, the Tandem Mass Tag (TMT)
system is used to label peptides following proteolytic digestions
(Thompson et al., 2003). TMT tags are covalently coupled
to both N-terminal α-amino groups and ε-amino groups
of lysine residues (Thompson et al., 2003). Once labeled,
peptide samples are pooled (commonly up to 10-plex), and

TABLE 4 | MALDI-MS proteomics studies for mechanistic insight into ALS and FTD.
Sample

Summary

Remarks

References

ALS spinal cord

CA-I is biotinylated alongside SOD1 +
immunoreactive to a SOD1 antibody

Suggests altered CO2 transport and cellular pH
homeostasis

Liu et al., 2010

sALS spinal cord

18 proteins ↑/↓, GFAP = most abundant

Proteins involved in apoptosis and cytoskeleton
stabilization

Ekegren et al., 2006

FTLD frontal cortex

24 proteins ↑/↓ = UCHL1 and oxidative stress
proteins

Ubiquitin-mediated degradation and oxidative
stress response altered

Schweitzer et al., 2006

Human samples

FTLD-tau (Pick disease) brain

↑ GFAP with glycoxidation and lipoxidation

GFAP = target of oxidative damage

Muntane et al., 2006

FTD temporal lobe

N-terminal fragment ProSAAS enriched in
tauopathies

ProSAAS is an inhibitor of neuroendocrine
peptide processing - enrichment may cause
functional perturbation

Kikuchi et al., 2003

FTD CSF

↑/↓ ProSAAS, PEDF, RBP, apoE, HP, and ALB

Comparative proteomics to establish
pathophysiological mechanisms

Davidsson et al., 2002

sALS spinal cord

↑ Detergent-insoluble proteins (ACO2, HSC70,
and PPIase A) + intermediate filaments,
chaperones and mitochondrial proteins, some
tyrosine-nitration

Aggregation-prone proteins and nitrative stress
contribution to inclusion pathology

Basso et al., 2009

SOD1G93A mouse synaptic
fractions

STAU1+dynein interactions via PP1B

STAU1 regulates mRNA localization in axons
and synapses. Disrupted = toxicity

Gershoni-Emek et al., 2016

SOD1G93A mouse facial and
trigeminal nuclei

↑/↓ various proteins, ↑RPS19

Proteins contributing to pathology via
comparative brain region proteomics

Acquadro et al., 2014

SOD1H46R/H48Q mouse spinal
cord

Association between SOD1 surface
hydrophobicity SOD1 and conformations

HSF1 activation may mitigate ALS pathology

Lin et al., 2013

SOD1G93A and G127X mouse
spinal cord

Mutant SOD1 interactors = chaperones,
HSC70 abundant

Chaperone depletion is not involved in SOD1
mutations of ALS

Zetterstrom et al., 2011

SOD1G85R and G93A mouse
eMNs

↑ CRMP4a = axonal degeneration and MN cell
death ↓ CRMP4a protective

CRMP4a pathologically involved in ALS

Duplan et al., 2010

SOD1G127X mouse spinal cord

54 proteins ↑/↓ = oxidative stress,
mitochondrial, cellular assembly/organization
and protein degradation

Altered pathways may contribute to disease

Bergemalm et al., 2009

SOD1G93A mice spinal cord

↑/↓ proteins = mitochondrial dysfunction,
aggregation and stress response

Potential presymptomatic targets

Massignan et al., 2007

SOD1G93A mouse spinal cord

↑ Carbonylation of SOD1, TCTP, UCHL1, and
CRYAB

Oxidative modification contributing factor to
ALS

Poon et al., 2005

SOD1G93A mouse spinal cord

Peroxidation of DRP-2, HSP70, and ENO1

Supports oxidative stress as a major
pathological mechanism

Perluigi et al., 2005

hTau40P301L mouse brain

↓ Complex I activity, ↑ antioxidant enzymes,
altered lipid peroxidation

Tau pathology involves mitochondrial and
oxidative stress

David et al., 2005

N2A cells expressing ATXN2,
FUS, C9ORF72, OPTN,
TDP-43, and UBLQN2
WT/mutants

Interactome of ATXN2, C9ORF72, FUS, OPTN,
TDP-43, and UBQLN2 (hundreds of proteins)

Strong interactome overlap for ATXN2, FUS,
and TDP-43 distinct from OPTN and UBQLN2

Blokhuis et al., 2016

C4F6 hybridoma cells
expressing SOD1 mutants

D92/D96 important for SOD1-C4F6 antibody
interaction

C4F6 antibody epitope in SOD1 is a potential
therapeutic target

Rotunno et al., 2014

COS7 cells expressing PGRN

4 N-glycosylation sites of PGRN

PGRN glycosylation may contribute to disease

Songsrirote et al., 2010

Animal models

Cell models and in vitro studies

(Continued)
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TABLE 4 | Continued
Sample

Summary

Remarks

References

N2A cells treated with cadmium

Cadmium = ↑/↓ proteins = cellular structure,
stress, chaperones, cell death/survival and ROS

Heavy metals suppress function of SOD1

Huang et al., 2006

NSC-34 cells expressing
SOD1G93A

170 proteins, ↑/↓ = mitochondrial, membrane
transport, apoptosis, respiratory chain and
chaperones

Mitochondrial protein changes = evidence for
mitochondrial dysfunction

Fukada et al., 2004

SOD1WT or N26D/N131D/N139D
isolated from yeast

Deamidation mimic mutant SOD1 aggregated
into amyloid fibrils faster than WT

Deamidation may be involved in SOD1
pathology

Shi et al., 2013b

In vitro (tau)

Acetylated tau prevents degradation of
phosphorylated tau

Tau acetylation may be a therapeutic target

Min et al., 2010

↑, denotes increase; ↓, denotes decrease; ACO2, aconitase; ALB, albumin; apoE, apolipoprotein E; ATXN2, ataxin-2; C4F6; CA-I, carbonic anhydrase I; CRMP4a,
collapsin response mediator protein 4a; CRYAB, alpha-crystallin B chain; CSF, cerebrospinal fluid; DRP-2, dystrophin-related protein 2; eMNs, embryonic motor neurons;
ENO1, alpha-enolase; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; FUS, fused-in sarcoma; GFAP, glial fibrillary acidic protein; HP, haptoglobin;
HSC70, heat shock cognate 71 kDA; HSP70, heat shock 70 kDa; OPTN, optineurin; PEDF, pigment epithelium-derived factor; PGRN, progranulin; PP1B, protein
phosphatase 1-beta; PPIase A, peptidyl-prolyl cis-trans isomerase A; ProSAAS, proprotein convertase 1 inhibitor; RBP, retinol binding protein; ROS, reactive oxygen
species; RPS19, 40S ribosomal protein S19; sALS, sporadic amyotrophic lateral sclerosis; STAU1, Staufen1; TCTP, translationally controlled tumor protein; TDP-43, TAR
DNA-binding protein of 43 kDa; UBQLN2, ubiquilin-2; and UCHL1, ubiquitin carboxy-terminal hydrolase L1.

disease states not only reveals normal protein function but also
sheds light on pathogenic changes. Characterizing PPIs also has
therapeutic value since specific interactions may be amenable to
therapeutic modulation.
MS-based methods enable high-throughput identification
of PPIs and have been extensively used to characterize the
interactomes of many proteins implicated in neurodegeneration
(Hosp et al., 2015). Standard methods used to identify PPIs are
based on an immunoprecipitation (IP) followed by MS; however,
in recent years, proximity-ligation methods have emerged
which complement standard IPs and provide additional insight
into protein interactomes. These methods include proximitydependent biotin identification (BioID) and ascorbate peroxidase
(APEX)-based proximity tagging (Roux et al., 2012, 2013; Chu
et al., 2017). BioID, APEX and related techniques can also be
used to study interaction partners of insoluble proteins, a feature
which makes these methods particularly useful when analyzing
neurodegenerative diseases characterized by protein aggregation
(Roux et al., 2013).

subsequently fractionated and analyzed by a high-resolution mass
spectrometer. The secondary detection of reporter ions (MS2)
allow the peptides to be quantitated based on the TMT signal
intensities, which can be extended to a third round (MS3) to
decrease ratio distortion (Ting et al., 2011).
TMT-based quantitative proteomics is being increasingly
applied in neuroscience, including in several investigations of
proteome-wide nucleocytoplasmic changes in cell-based models
of ALS. In mouse motor neuron-like NSC-34 cells overexpressing
mutant hSOD1G93A , TMT-labeling of peptides combined with
the results of RNA-Seq demonstrated impairments to nuclear and
cytoplasmic transport (Kim et al., 2017). Specifically, proteins
enriched in the nuclear fraction of mutant SOD1-expressing
cells were related to RNA transport/processing and known
Huntington’s disease/Alzheimer’s disease pathways, whilst
proteins enriched in cytoplasmic fractions were involved in
protein folding, aminoacyl-tRNA biosynthesis, Wnt signaling,
synaptic vesicle cycle and Hippo signaling pathways (Kim et al.,
2017). In another study, TMT 10-plex was used to analyze ALS
patient fibroblast-derived iPSC cells to validate genome-wide
RNA instability in ALS and FTD patients (Tank et al., 2018).
Bromouridine tagging of RNA transcripts identified profound
destabilization of ribosomal and mitochondrial transcripts,
which was verified by TMT-quantitative proteomics and revealed
corresponding decreases in mitochondrial components and
compensatory increases in protein synthesis (Tank et al.,
2018). This approach suggested that RNA instability could be
a targeted effect of TDP-43 accumulation, disrupting energy
production and protein synthesis, culminating in cell death
(Tank et al., 2018). A summary of studies that have used various
labeling-based MS techniques such as TMT for investigation of
ALS and FTD is presented in Table 5.

Immunoprecipitation and MS (IP-MS)
A standard method that is used to identify PPIs relies on
maintaining the physical interaction between the interaction
partners. Prior to IPs, cells are lysed in non-denaturing buffers
which can maintain stable but not transient interactions.
A typical process for IP-MS studies is based on antibody
recognition of a protein of interest within a lysate, followed
by specific isolation of the antibody (and associated proteins)
using protein A or G conjugated to beads (Markham et al.,
2007). Of note, this method requires that PPIs remain stable
after cell lysis and that the protein complex of interest remains
soluble in the chosen lysis buffers. In ALS and FTD studies,
IP-MS has been used to identify interacting partners of TDP-43,
revealing many proteins involved in RNA metabolism (Freibaum
et al., 2010). Recently, identified interactors of RNA-binding
protein 45 (RBM45), a protein that colocalizes with ALS and
FTD inclusions, were associated with multiple hnRNP and EIF
proteins involved in RNA metabolism, suggesting disturbance

Protein-Protein Interactions
Interrogating PPIs in cultured cells, animal models of disease
and from human tissue can provide valuable insight into
mechanisms that underlie neurodegeneration. Characterizing
the interactome of proteins of interest in both healthy and
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TABLE 5 | Labeled-MS proteomics studies for mechanistic insight into ALS and FTD.
Technique

Model

Summary

Remarks

References

iTRAQ

SOD1G93A mouse spinal cord

↑ 676 proteins, ↓ 480 proteins

Preliminary insight into altered
proteins

Zhang J. et al., 2018

iTRAQ

Rat neonate spinal cord injected
with ALS CSF

↓ 35 mitochondrial and 4 lysosomal
proteins and ↑ BNIP3L

Mitochondrial and lysosomal
defects involved in pathogenesis

Sharma et al., 2016

SILAC

HeLa cells expressing FUS/TLS

↑ FUS/TLS mutant interaction with
SMN and ↓ interaction with
U1-snRNP

Demonstrates a gain and loss of
function in FUS-ALS

Sun et al., 2015

SILAC

Primary mouse astrocyte cultures

60 astrocyte proteins regulate
secretion with Ang stimulation

Ang taken up by
astrocytes = potential
neuroprotection

Skorupa et al., 2013

SILAC

HEK-293 cells expressing TDP-43
or splice variant

35 proteins co-aggregate with
TDP-43 (G3BP, PABPC1 and
eIF4A1), 4 ubiquitinated sites on
TDP-43 splice variant

TDP-43 aggregation partners +
ubiquitination affects
oligomerization

Dammer et al., 2012

SILAC and label-free

H1299 cells and HEK293T cells
expressing UBXD1 or ERGIC-53

Interactome of UBXD1 includes
VCP and ERGIC-53, highlighting its
role in vesicle trafficking

UBXD1 involved in regulation of
ERGIC-53 trafficking through its
interaction with VCP

Haines et al., 2012

SILAC and label-free

HeLa cells expressing TDP-43

TDP-43 interacts with hnRNP,
Drosha and FUS/TLS complexes,
mutant TDP-43 ↑ FUS/TLS
interactions

TDP-43 involved in mRNA
processing and miRNA biogenesis,
function overlap with FUS

Ling et al., 2010

TMT

C9ALS and sALS iPSCs

RNA stability/binding targets: ↑/↓
170 altered in C9ALS and 121 in
sALS

Destabilization of RNA transcripts
involved in oxidative
phosphorylation and ribosomal
machinery

Tank et al., 2018

TMT

hESC and hESC MN cells
expressing C9ORF72,
immunoprecipitated

C9ORF72 stabilizes SMCR8,
enables interaction with WDR41

C9ORF72+SMCR8 involved in
autoimmunity and lysosomal
exocytosis

Zhang Y. et al., 2018

TMT

HeLa cells expressing C9ORF72
DPR proteins

C9ORF72 PR and GR DPRs block
spliceosome assembly

DPR-mediated
dysfunction = Mis-spliced exons in
C9ORF72

Yin et al., 2017

TMT

C57BL/6J tau KO mouse brain

Interactome of tau and isoforms –
101 proteins identified

Selective binding of proteins with
specific isoforms of tau

Liu et al., 2016

TMT and iTRAQ

HEK293T and SH-SY5Y expressing
various tau proteins

TauP301L disrupts interactions with
heat shock, proteasome and
microtubule-associated proteins

Mutant tauP301L ↓ interactions with
chaperones and proteasome

Gunawardana et al., 2015

↑, denotes increase; ↓, denotes decrease; Ang, angiogenin; BNIP3L, BCL2 interacting protein 3-like; CSF, cerebrospinal fluid; DPR, dipeptide repeat; eIF4A1, eukaryotic
translation initiation factor 4A1; ERGIC-53, ER-Golgi intermediate compartment 53 kDa protein; FTD, frontotemporal dementia; FUS, fused-in-sarcoma; G3BP, ras
GTPase-activating protein; GR, glycine arginine; hESC, human embryonic stem cell; iTRAQ, isobaric tags for relative and absolute quantitation; KO, knockout; MN, motor
neuron; PABPC1, polyadenylate-binding protein 1; PR, proline arginine; sALS, sporadic amyotrophic lateral sclerosis; SILAC, stable isotope labeling by amino acids in
cell culture; SMCR8, guanine nucleotide exchange protein; SMN, survival motor neuron protein; TDP-43, TAR DNA binding protein of 43 kDa; TMT, tandem mass tag;
UBXD1, UBX domain-containing protein 1; VCP, valoslin-containing protein; and WDR41, WD repeat-containing protein 41.

studies of both detergent-soluble and -insoluble proteins from
cells and tissues.

of these processes upon pathology formation in disease (Li
et al., 2016). As IP-MS studies generally incorporate labelfree MS they have been included amongst studies previously
discussed in Tables 1–3.

Proximity-dependent biotin identification (BioID)
Proximity-dependent biotin identification or BioID is based
on the use of an engineered biotin ligase which carries an
R118G mutation within its active site, effectively nullifying
self-association and DNA binding (Roux et al., 2012). Normally,
biotin ligase (BirA) works by converting biotin to a highly
reactive biotinoyl-AMP intermediate in an ATP-dependent
manner. This intermediate is then deposited onto lysine residues
within the natural substrate of BirA, Biotin Carboxyl Carrier
Protein (BCCP) (Cronan, 1990). Engineered biotin ligase (BirA∗ )
is also able to convert biotin to a highly reactive intermediate,
however, due to this R118G mutation, the intermediate is
prematurely released from the active site of BirA∗ and diffuses

Proximity-Ligation Methods
BioID and APEX are proximity-ligation methods which facilitate
the covalent attachment of biotin onto proteins in close
proximity to a protein of interest. The application of these
methods for interrogating PPIs of proteins is based on the
strong interaction between biotin and streptavidin (Green,
1990) and the stability of streptavidin in a large range
of conditions. This includes stability in denaturing buffers
containing ionic detergents such as sodium dodecylsulfate (SDS)
(Sano et al., 1998) and chaotropic reagents such as urea (Kurzban
et al., 1991), such that these approaches are applicable to
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to 20 nm (Chu et al., 2017). After 1 min, the reaction is
stopped with quenching buffer to prevent further biotinylation
post-lysis. Cells may then be lysed before biotinylated proteins
are isolated by streptavidin conjugated to beads and identified
using MS-based workflows. An advantage of the short labeling
timeframe is that APEX can be used to capture dynamic
changes in PPIs. This may become advantageous for time
course studies where protein interactions may dynamically
change in response to various stimuli such as cell stress or
drug treatments.
APEX can also be applied to analysis by electron microscopy
(EM) (Martell et al., 2012; Lam et al., 2015), thereby enabling
the interrogation of protein localization at high resolution. Here,
fusion proteins are expressed in cells before cells are fixed and
treated with diaminobenzidine (DAB) and H2 O2 (Lam et al.,
2015). APEX catalyzes the polymerization and local deposition
of DAB in the vicinity of the fusion protein, enabling subsequent
recruitment of electron dense osmium for EM applications
(Lam et al., 2015).
By applying APEX for both proteomics and EM workflows,
APEX can be used to characterize dynamic changes in
the protein interactome of live cells whilst also accurately
defining protein localization at high resolution. In recent
years, variations of APEX have emerged. This includes APEX2
(Lam et al., 2015) which has improved catalytic efficiency
and split APEX (sAPEX) which enables the interrogation of
two known protein interaction partners or proteins known
to be in close proximity (Han et al., 2018). Recently, the
APEX technique has been applied to profile the components
of stress granules, which are enriched in RNA-binding proteins
including the ALS/FTD-linked proteins TDP-43 and FUS
(Markmiller et al., 2018). Notably, these studies revealed
previously unrecognized stress granules (SGs) proteins that also
displayed alterations in induced pluripotent stem cell-derived
motor neurons from ALS patients and for which modulation of
expression was protective in Drosophila ALS models, suggesting
disturbances in SGs may be related to disease pathogenesis
(Markmiller et al., 2018).

away leading to biotinylation of nearby lysine residues (Kwon
et al., 2000). In this way BirA∗ can biotinylate lysine residues of
proteins in close proximity to the protein of interest. In a typical
BioID workflow, a construct encoding BirA∗ in frame with a
protein of interest is first generated and expressed in live cells.
Exogenous biotin is then added to cell culture media such that
biotin can be processed by BirA∗ and deposited onto proteins
within proximity to the fusion protein. Here, labeling typically
occurs over 12–24 h to generate enough material for analysis. In
addition, the half-life of the biotin intermediate is in the minutes
range which results in a large labeling radius (Rhee et al., 2013).
Cells can then be lysed before streptavidin-conjugated beads are
used to isolate biotinylated proteins from the complex mixture.
These isolated biotinylated proteins can then be identified
using standard MS-based workflows. BioID approaches have
only recently begun to be applied to studies to understand
mechanisms of ALS and FTD and discussion continues into
their use for neurodegenerative diseases (Rayner et al., 2019).
Most notably, a BioID approach was used to characterize
the interactome of TDP-43 and a C-terminal fragment which
revealed a correlation between C-terminal fragments and nuclear
pore defects (Chou et al., 2018).
In recent years, a smaller, more efficient form of the biotin
ligase, termed BioID2, has been established (Kim et al., 2016).
BirA∗ has also been modified using directed evolution which has
improved the labeling kinetics of biotin ligase such that labeling
can be completed in 10 min. This variant of BirA∗ , termed
“TurboID” has been implemented in live organisms including
Caenorhabditis elegans and Drosophila melanogaster (Branon
et al., 2018), demonstrating the versatility of this method to
interrogate the interactome of proteins in both live cells and
organisms. These improvements make this system a key new
technology for future application to the understanding of protein
interactions in neurodegeneration, using both cultured cells and
animal models of disease.

Ascorbate peroxidase (APEX)-based proximity tagging
APEX is a 28 kDa engineered peroxidase that is derived
from dimeric pea or soybean ascorbate peroxidases (Martell
et al., 2012; Rhee et al., 2013). APEX can be used in a
similar manner to BioID for the biotinylation of proteins in
the vicinity of a protein of interest. Like BioID, constructs
are first generated to encode engineered soybean peroxidase
in frame with a protein of interest before the fusion protein
is expressed in live cells. Notably, APEX can be used for
temporally resolved proteomics as well as high-resolution
microscopy, making this a flexible technique for studies of
protein interactions.
Once the APEX fusion protein is expressed in live cells,
exogenous biotin is added to cell culture media. For labeling
of proximal proteins, hydrogen peroxide (H2 O2 ) and biotin
phenol is added to media such that APEX can catalyze a
one-electron oxidization of biotin phenol to a biotinphenoxyl
radical which subsequently biotinylates proteins in proximity
(Lam et al., 2015). Notably, labeling kinetics of APEX is fast.
The produced biotin-phenoxyl radical lasts for <1 ms which
enables labeling times of 1 min and limits the labeling radius
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Future Applications of Proximity Labeling
Techniques
Biotinylation by Antibody Recognition (BAR) is another
proximity-labeling technique which has recently been established
for investigating PPIs in fixed samples (Bar et al., 2018). Here,
cultured cells or tissue are fixed and permeabilized before
a primary antibody is used to target a protein of interest.
A secondary antibody conjugated to horseradish peroxidase
(HRP) is then used to recognize the primary antibody, and
labeling of proximal proteins is achieved by HRP in the
presence of H2 O2 and biotin phenol. The conjugation of biotin
enables the isolation of these proximal proteins. Although
this method has not yet been applied for the study of
neurodegenerative diseases, it is a promising technique for future
analysis of proteins involved in ALS and FTD and may be
particularly useful for analysis of detergent-insoluble protein
aggregates and inclusions.
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and are sensitive to sample preparative steps that include
high and low pH buffers, trypsinization, and de-salting steps
(Wei and Li, 2008; Olsen and Mann, 2013). To circumvent
many of the issues associated with analyzing PTMs such as
ubiquitination and phosphorylation, enrichment strategies to
isolate peptides containing these modifications together with
quantitative proteomic approaches can provide a more in-depth
analysis of the sub-proteome.

Analysis of Protein Post-translational
Modifications in ALS and FTD
Post-translational modifications provide the basis of biological
diversity in the proteome by enabling the same protein to
carry out diverse functions through characteristic variations
of modifications and their temporal regulation. PTMs are
small, covalent, amino acid modifications added onto a protein;
they are highly dynamic and play key roles in selectively
regulating protein function in cells, tissue, and biofluids,
such as CSF (Guldbrandsen et al., 2014). PTMs regulate
most aspects of intracellular function involving but not
limited to, DNA repair, proliferation, subcellular localization,
transport, and proteolytic cleavage of functional units or protein
degradation. On a larger scale PTMs also modulate intercellular
functions like cell signaling and adhesion (Minguez et al., 2012;
Theillet et al., 2012; Olsen and Mann, 2013). Various types
of PTMs exist (Prabakaran et al., 2012), with arguably the
most studied in proteostasis and neurodegenerative diseases
being: ubiquitination, phosphorylation, nitration, acetylation,
oxidation, glycosylation, methylation, and sumoylation
(Minguez et al., 2012).
Pathological phosphorylation of proteins such as tau,
TDP-43, α-synuclein or FUS contribute to the formation of
protein inclusions in neurodegenerative disease (Hasegawa
et al., 2008; Despres et al., 2017; Monahan et al., 2017;
Cykowski et al., 2018). For example, tauopathies caused by
the phosphorylation of tau in FTD and AD are comprised
of aggregated proteins in fibrillary tangles (Ferrer et al.,
2002). While the underlying mechanisms of misfolded protein
aggregation and neurotoxicity in neurodegeneration is not yet
understood, PTMs such as ubiquitination are of interest given
their regulatory role in protein degradation. For example, the
temporal regulation of phosphorylation and ubiquitination
in protein signaling cascades, and hyperubiquitination
by mutant cyclin F cause defects to protein degradation
pathways that are associated with ALS/FTD (Lee A. et al.,
2017). Furthermore, other examples of aberrant PTMs
include acetylation of glial fibrillary acidic protein in ALS
(Liu et al., 2013), acetylated TDP-43 in ALS (Wang et al.,
2017) and sialylation of amyloid precursor protein in AD
(Nakagawa et al., 2006).

Ubiquitination
A popular enrichment strategy for identifying ubiquitination
sites on peptides called diglycine (diGLY) enrichment exploits
the cleavage sites (K-ε-GG) of ubiquitinated proteins following
trypsin digestion (Kim et al., 2011). The covalent attachment
of ubiquitin on lysine residues on proteins allows trypsin to
cleave both the C-terminus of ubiquitin and the C-terminus of
the lysine amino acid on the ubiquitinated protein exposing two
glycine residues. Ubiquitin remnant motif (K-ε-GG) antibodies
are used to enrich peptides containing the di-Gly-Gly motif,
followed by elution and analysis by LC-MS/MS in which the
presence of the GlyGly residue on lysine (+m/z 114.04) in the
MS spectra is an indication of a ubiquitinated peptide (Peng
et al., 2003; Xu et al., 2010; Fulzele and Bennett, 2018). However,
ubiquitin-like proteins also exist that may be identified using this
method such as SUMO (sumoylation), NEDD8 (neddylation)
and interferon-stimulated gene 15 (ISG15; isg15ylation) also
known as ubiquitin cross-reactive protein (UCRP) (Hemelaar
et al., 2004). Quantitative assessment of the stoichiometry of
site-specific ubiquitination can be achieved using the recently
reported “isotopically balanced quantification of ubiquitination”
(IBAQ-Ub) method which employs an amine-reactive chemical
tag (AcGG-NHS) that is structurally homologous to a tryptically
cleaved ubiquitinated peptide containing a GG remnant of
ubiquitin on the modified lysine residue. These AcGG-NHS
tagged peptides allows the generation of structurally identical
peptides from ubiquitinated and unmodified lysine residues that
can be further labeled using a secondary stable isotope (Li et al.,
2019). Other areas which are generating interest are investigating
the specific poly-ubiquitin linkages, in which isotope-labeling of
the lysine residues in ubiquitin can be used, such as “UB-AQUA”
and detected by high resolution MS via narrow window extracted
ion chromatogram or by selected reaction monitoring (SRMMS) using a triple quadrupole MS (Phu et al., 2011). Overall,
these various methods enable stoichiometric analysis of the polyubiquitin modifications on target proteins, which could provide
insights into the ubiquitin code underlying altered protein
degradation in neurodegeneration.

Detecting PTMs by Mass Spectrometry
Many PTMs can be mapped by tandem MS (MS/MS)
(Dephoure et al., 2013), which offers an unbiased approach
that can be verified by alternative biochemical methods such as
immunoblotting and immunofluorescence microscopy. To date,
the presence of PTMs such as ubiquitination, phosphorylation,
acetylation, and nitration, and their stoichiometric analysis
have been enabled by qualitative and quantitative proteomics,
respectively, on a global proteomic scale in ALS-linked proteins
(Sacksteder et al., 2006; Liu et al., 2013; Shi et al., 2013a; Lee
A. et al., 2017; Wang et al., 2017). Despite the capabilities
of MS to identify PTMs, they are often difficult to detect as
they vary in physiochemical properties, can exist as transient
modifications, be present in sub-stoichiometric concentrations
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Phosphorylation
Protein aggregates containing phosphorylated proteins is a key
pathological feature in many neurodegenerative diseases, such
as phospho-tau in Alzheimer’s disease and FTD (Sjogren et al.,
2001), phospho-TDP-43 in ALS and FTD (Hasegawa et al., 2008)
and phospho-alpha-synuclein in Parkinson’s disease (Wang
et al., 2012). Phosphorylation of serine, threonine, and tyrosine
residues are generally the most common sites in mammals,
which are estimated to compromise of approximately 90, 10,
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and <1% of the total phosphoproteome, respectively (NitaLazar et al., 2008). The main challenges with characterizing
phosphorylated proteins using MS is the direct detection of
low stoichiometric concentrations of phosphopeptides resulting
from trypsin digestion of complex samples. This is further
complicated by ion suppression of phosphopeptides due to
the negative charge and lability of the phosphate moiety.
Therefore, many approaches have been developed to enrich
phosphopeptides prior to MS-based analysis, including titanium
dioxide (TiO2 ), immobilized metal affinity chromatography
(IMAC), and hydrophilic interaction chromatography (HILIC),
discussed elsewhere (Arrington et al., 2017). The detection of
a phosphopeptide can be interpreted by the neutral loss of
H3 PO4 (-m/z 98) in the mass spectra. Many algorithms have
been developed for interpreting MS/MS fragmentation spectra
and phosphorylation site localization such as Mascot Delta Score
(Savitski et al., 2011), PhosphoRS localization (Taus et al., 2011)
and PTM score of MaxQuant (Cox and Mann, 2008). These
algorithms match the spectra generated to a protein sequence
database of choice (e.g., UniProtKB/Swiss-Prot) to assign the
probabilities of potential phosphorylation sites.
Previously, sarkosyl-insoluble pathological TDP-43 from
brains of two ALS patients were purified and subjected to
LC-MS/MS analysis, identifying several novel phosphorylation
sites, deamidation sites, and cleavage sites (Kametani et al.,
2016). Seventeen phosphorylation sites were identified from both
ALS patients which were predominately located in the Gly-rich
C-terminal region on TDP-43, while most of the cleavage
sites were located in N-terminal half, suggesting that these
sites may be more accessible to proteolytic enzymes (Kametani
et al., 2016). Immunoblot analysis using the phospho-specific
TDP-43 S409/410 antibody, which recognizes the abnormal
phosphorylation of Ser409 and 410, verified the presence of
pathological phospho-forms of TDP-43 and additional fragments
of 18∼24 kDa. These findings indicate that phosphorylation plays
an important role in the mechanism of TDP-43 pathogenesis,
and suggests that enrichment strategies to comprehensively
characterize the phosphoproteome are highly relevant to
understanding neurodegenerative diseases.

Pattern-Matching rule” and not all organisms have a complete
protein sequence reference.
De novo peptide sequencing generates a list of all the
highest scored peptides from the MS/MS spectra and the
mass values given without the need of a reference database.
With high resolution mass spectrometers producing quality
data, the performance of de novo sequencing has remarkably
improved. However, a significant caveat pertains to resolving
amino acids with or without modifications, due to either identical
mass or near-identical masses. In addition, there is an inverse
relationship between the accuracy of this method and peptide
length (Muth and Renard, 2018). New strategies are being
created in this space to overcome these limitations, such as post
novo, which post-processes de novo sequence filter prediction
(Miller et al., 2018).
Commonly used bioinformatics programs such as STRING
(Szklarczyk et al., 2019), BioGrid (Oughtred et al., 2019),
Ingenuity Pathway Analysis (IPA) (Yu J. et al., 2016), and
DAVID (Huang da et al., 2009) are frequently used to interrogate
the data obtained from large scale quantitative proteomic
experiments to get a snapshot of the expressional changes
that occur within a sub-proteome. Notably, depending on
the biological question, these informatics tools can assist in
quickly identifying networks, pathways and functions to facilitate
further experiments and generate new hypotheses. For example,
proteomics data generated from IP of TDP-43 from HEK293
lysates were analyzed by STRING, which demonstrated clear
nuclear and cytoplasmic interaction networks (Freibaum et al.,
2010). Assigning protein functions using bioinformatics software
therefore provides a higher-level overview into changes and
perturbations occurring during disease, for example allowing
the identification of disease relevant biochemical pathways.
A more detailed review of the bioinformatics tools used
for proteomics is discussed elsewhere (Schmidt et al., 2014;
Martens and Vizcaino, 2017).

Flow Cytometric Purification of Inclusion
Bodies Associated With ALS and FTD
Determination of the composition of insoluble inclusions formed
in many neurodegenerative diseases is key to understanding
pathogenesis. The use of proteomics will allow greater
understanding of the global protein composition of these
inclusions and allow us to identify proteins and cellular pathways
that are either involved in the assembly or attempted disassembly
of the inclusion, and distinguish these from proteins that
were non-specifically sequestered. Comparing the protein
composition of inclusions formed from a variety of pathogenic
proteins (e.g., TDP-43- or SOD1-positive inclusions in ALS)
could also help to establish common pathways involved in this
process across different types of neurodegenerative diseases.
Fluorescence activated cell sorting (FACS) is one technique
that can be used to purify insoluble protein or inclusions
from cell culture or tissues. Regarding cell-based models
of neurodegenerative disease-associated protein aggregation,
gentle plasma membrane permeabilization in combination with
FACS could be employed to purify inclusions for proteomic
analyses. A method for this was recently described, whereby

Bioinformatics
Tandem mass spectra generated by MS are analyzed using
specialized software and algorithms to identify and quantitate
peptides and proteins using two main approaches: database
search and de novo search. Database searching follows the
“Exact Pattern-Matching rule,” which consists of only selecting
spectra masses that exactly match a sequence in a multispecies- or species-specific database. The most frequently
used programs with a database search implemented are
SEQUEST (Eng et al., 1994), Mascot (Perkins et al., 1999),
and X!Tandem (Craig and Beavis, 2004). These programs
not only extract candidate proteins using a combination of
the open access database and their own in-built database
but also score them using algorithms based on the ion
signals observed in the spectra. Some limitations of the
database search method include that a large portion of
acquired spectra will be rejected because of the “Exact
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necessarily conflicting but highlight the importance of validation
across multiple large cohorts for biological relevance.
In recent years, an increased number of small and large-scale
biomarker studies have been performed on human ALS samples
by LFQ, as recently reviewed (Barschke et al., 2017). CSF from
ALS, primary lateral sclerosis (PLS), cross-sectional healthy and
disease controls (Parkinsons’ disease and ALS mimic disorders)
were analyzed via LFQ for novel biomarker discovery (Thompson
et al., 2018). Elevation in levels of chitotriosidase, chitinase-3-like
protein 1 and chitinase-3-like protein 2 in a cohort of 43 patients
with ALS has been revealed, indicating neuroinflammation due
to increased microglial activation (Thompson et al., 2018). No
direct validation was performed to confirm the proteomic data,
although reference to previous ELISA studies of these chitinase
proteins in ALS patient samples (likely including some from the
same cohort), suggested a similar trend (Varghese et al., 2013).
Biofluid sample usage is prominent due to the need for
a directly translatable and easily retrievable marker for rapid
and accurate diagnosis. Alongside disease diagnosis, the ability
to distinguish between subtypes of a disease would prove
instrumental in developing personalized treatments. Whilst
many studies have identified altered proteins across cohorts of
patients, others focus on teasing apart unclear differences such as
those found in subtypes of FTD (Teunissen et al., 2016). Recently,
a CSF-wide proteomic analysis was performed to highlight the
usefulness of biofluid MS for biomarker elucidation, identifying
relevant disease-related proteins such as tau (Macron et al.,
2018). In the context of biomarker discovery, newer labeled
methods are being utilized to narrow down on protein hits of
interest due to the greater quantitation accuracy compared to
label-free methods (Megger et al., 2014). A summary of ALS
and FTD biomarker elucidation studies in the last decade that
have used both label-free and labeled methods is presented in
Table 6. Ultimately, it is crucial to have a clear biological question
to pursue for selection of sample, technique and subsequent
validation approaches, although unbiased screening of potential
disease-related biofluid alterations may help identify previously
unrecognized research directions.

cells are permeabilized with 0.5% (v/v) TritonX-100 in PBS
supplemented with protease/phosphatase inhibitors to quantify
and characterize inclusions comprised of fluorescently tagged
proteins of interest by flow cytometry (Whiten et al., 2016).
This work also demonstrated that fluorescent aggregates and
nuclei can be sorted by FACS (Whiten et al., 2016). Alternatively,
cells can be treated with 0.03% (w/v) saponin to selectively
permeabilize the plasma membrane, allowing soluble proteins
to diffuse out of the cytoplasm, while retaining the nucleus
and inclusions intact (Farrawell et al., 2018; Pokrishevsky
et al., 2018). These treated cells can be washed to remove
the soluble proteins that have diffused out of the cells and
subsequently purify cells with inclusions by FACS. It follows
that inclusions comprised of fluorescently tagged proteins, or
fluorescent antibody-labeled inclusions can be purified by FACS
from cells and tissues and subjected to proteomic analysis to
determine their composition.
Purification of inclusions by FACS for proteomic analysis has
previously been adopted to investigate the protein composition
of Huntington’s disease-associated polyglutamine inclusions
(Mitsui et al., 2002, 2006). Using this strategy, heat shock
protein 84 and elongation factor 1α were identified as novel
inclusion-interacting proteins and their over-expression in
cell-based assays demonstrated cytoprotective activities (Mitsui
et al., 2002, 2006). Future experiments could employ this strategy
to purify insoluble protein and inclusions for proteomic analysis
from ALS/FTD patient samples, rodent tissues, or cell-based
models of ALS/FTLD.

BIOMARKER STUDIES OF ALS AND FTD
As high-throughput technologies have advanced, many
proteomic-based biomarker studies have presented an
abundance of potential candidates; however, it is often not
feasible to properly validate each individual protein considering
the heterogeneity amongst different patient cohorts, which can
hinder the level of accuracy and reproducibility. Selection of
which candidates to validate is not clearly defined, uniform, or
standardized. This selection can be made based on a combination
of statistics, current literature as well as assessed potential based
on PPIs, both predicted and real.
One of the major issues that arises as a result of subjective
validation is the variation of proteins identified across parallel
studies, rarely reinforcing the previously presented data. For
example, measurements of HeLa cells prepared identically
and analyzed across different laboratories using the same
instrumentation revealed a high level of biological heterogeneity
on both transcriptomic and proteomic levels (Liu et al., 2019).
This occurs for a number of reasons, including the sample
composition and sample cohorts, environmental conditions
affecting instrument parameters, as well as technical variation
due to extraction/digestion procedures (Piehowski et al., 2013).
Alternatively, the same protein could be reported with differing
results across samples, such as decreased levels of galectin-3 in
the plasma of SOD1 mice (Zubiri et al., 2018) and increased
levels in human CSF (Zhou et al., 2010). These results are not
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FUTURE DIRECTIONS AND
CONCLUSION
The technologies presented in this review have demonstrated
their utility when applied to neurodegenerative diseases such
as ALS and FTD. However, there needs to be a focus
on validating the research laterally, solidifying findings to
progress with ensuing biological questions. Incorporation of
parallel approaches such as transcriptomics using RNASeq
alongside results from proteomics can reinforce potential hits
of interest. Studies have successfully combined transcriptomic
and proteomics findings to provide mechanistic insights, such
as the finding of lysosomal changes in Grn-/- mice that are
modulated by the FTD-risk protein TMEM106B (Klein et al.,
2017). Additionally, recent advances in this area have included
correlation of transcriptomic findings with underlying TDP-43
pathology burden in a study of ALS spinal cord laser-capture
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TABLE 6 | Biomarker discovery studies using proteomics for ALS and FTD.
Technique

Sample

Summary

Remarks

References

iTRAQ

ALS CSF

↓ IGF-2, ↑ GRIA4 (levels correlate with
ALS severity)

Potential biomarker for disease severity
(gender differences)

Chen et al., 2016

iTRAQ

sALS CSF

31 proteins ↑ in ALS CSF, ↑ CHIT1 10x

CHIT1 expression = ↑ microglial activity
(potential CSF biomarker)

Varghese et al., 2013

Label free

TDP-43/Tau FTD CSF
and blood

56 proteins ↑/↓ in FTD subtypes
(notably CHI3L-1 and CAT)

Requires validation in FTD pathology
cohorts

Teunissen et al., 2016

Label-free

ALS CSF and plasma

27 proteins ↑/↓ in ALS CSF, 20
proteins ↑/↓ in ALS plasma (Validated
CHI3L-1 and ACT)

New and previously identified potential
biomarkers

Bereman et al., 2018

Label-free

ALS CSF

↑ CHIT1, CHI3L-1, and CHI3L-2

Neuroinflammatory mechanisms
implicated through microglial activation

Thompson et al., 2018

Label-free

sALS plasma

Serum proteome characterization

Lipid homeostasis proteins implicated

De Benedetti et al., 2017

Label-free

sALS CSF

WDR63, APLP2, SPARCL1, and
CADM3 = potential biomarkers

Panel of CSF proteins for biomarkers

Collins et al., 2015

Label-free

sALS and other neural
diseases

↑ MyBP-H potential ALS biomarker
compared to other motor neuropathies

↑ MyBP-H = attempted regeneration

Conti et al., 2014

Label-free

SOD1G93A mouse
spinal cord, ALS spinal
cord/CSF

14 proteins ↑/↓, ↑ Gal-3 in ALS

Comparative study of mouse and
human ALS

Zhou et al., 2010

Label-free (MRM)

ALS and FTD blood,
CSF and brain

TDP-43 in CSF appears to originate
from the blood

TDP-43 in blood and CSF not a viable
biomarker

Feneberg et al., 2014

Label-free (SRM)

SOD1G93A mouse
muscles

Shift in fiber-type composition of
hindlimb muscles

Diagnostic-prognostic tool for
neuromuscular diseases via myosin
heavy chain isoform?

Peggion et al., 2017

MALDI

ALS blood

↑/↓blood coagulation proteins

SVM-based model with >97%
recognition capability and >90%
specificity and sensitivity

Conraux et al., 2013

MALDI

SOD1G93A mouse
muscle

↑/↓ muscle albumin, complex I,
complex II, citrate synthase, FAS, PI3K,
PGC1α, SEMA-3A semaphorin-3A,
ROCK1

Potential dysmetabolism molecular
signatures in ALS

Capitanio et al., 2012

MALDI

sALS and SOD1G93A
rat blood

↑/↓ ER stress, nitrative stress, redox,
RNA metabolism proteins

Related to pathogenic mechanisms in
ALS

Nardo et al., 2011

MALDI

sALS and SOD1G93A
rat blood

↑ protein nitration early in disease

Nitrated proteins = presymptomatic
biomarker for ALS

Nardo et al., 2009

MALDI and
label-free

sALS and fALS
(nonSOD1) plasma

GC2 allele of DBP = potential risk factor
for fALS

Small cohort, requires validation

Palma et al., 2008

SILAC

ALS fibroblasts

33 proteins ↑/↓ (↓ ApoB48 and
HSP20, ↑ FIBL-1)

Potential biomarkers/therapeutic
targets

Narayan et al., 2016

Stable isotope
dimethyl-labeling

ALS tibialis anterior
muscle

↑/↓ KBTBD10, MYL3, AGL, and VCP

Potential muscle biopsy biomarkers
and therapeutic targets

Elf et al., 2014

SWATH

ALS plasma

↑/↓ GSN, APOJ, CDL5, and FCN3

↓ coagulation pathway proteins and ↑
complement pathway proteins

Xu et al., 2018

TMT

SOD1G93A mouse and
sALS plasma

↑/↓ApoE in human and Gal-3, CD61
and TGF-β1 in SOD1G93A mice

Altered immunosenescence and
metabolic markers

Zubiri et al., 2018

↑, denotes increase; ↓, denotes decrease; ACT, alpha-1-antichymotrypsin; AGL, glycogen debranching enzyme; APLP2, amyloid-like protein 1; ApoE, apolipoprotein E;
CADM3, cell adhesion molecule 3; CAT, catalase; CD5L, CD5 antigen-like; CD61, integrin beta 3; CHI3L-1, chitinase 3-like protein 1; CHI3L-2, chitinase 3-like protein
2; CHIT1, chitotriosidase-1; CSF, cerebrospinal fluid; DBP, vitamin D-binding protein; fALS, familial amyotrophic lateral sclerosis; FAS, tumor necrosis factor receptor
superfamily member 6; FCN3, ficolin 3; FIBL-1, fibulin-1; FTD, frontotemporal dementia; Gal-3, galectin-3; GRIA4, glutamate receptor 4; GSN, gelosin, APOJ, clusterin;
IGF-2, insulin growth factor II; iTRAQ, isobaric tags for relative and absolute quantitation; KBTBD10, BTB and kelch domain-containing protein 10; MALDI, matrix-assisted
laser desorption ionization; MRM, multiplex reaction monitoring; MYL3, myosin light chain 3; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1alpha; PI3K, phosphoinositide 3-kinase; ROCK1, rho-associated protein kinase 1; sALS, sporadic amyotrophic lateral sclerosis; SEMA-3A, semaphorin-3A; SILAC, stable
isotope labeling by amino acids in cell culture; SOD1, superoxide dismutase 1; SPARCL1, SPARC-like protein 1; SRM, selected reaction monitoring; SWATH, sequential
window acquisition of all theoretical mass spectra; TDP-43, TAR DNA binding protein of 43 kDa; TGF-β1, transforming growth factor beta-1; TMT, tandem mass tag; VCP,
transitional ER ATPase; and WDR63, WD repeat-containing protein 63.

dissected motor neurons (Krach et al., 2018). This was one of
the first studies to utilize overlapping distinct datasets to stratify
patient cohorts to identify the more relevant and important
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proteins involved in disease. Previously, careful patient sub-type
selection has led to the identification of genetic contributors
to disease, such as the finding that TMEM106b genotype is
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a risk modifier of FTD by GWAS of a highly specific and
well-defined subgroup of FTLD samples with confirmed TDP-43
histopathology (Van Deerlin et al., 2010). These findings suggest
that planning sample selection to allow multiple comparisons of
disease subtypes, alongside the combined use of new protein- and
RNA-profiling technologies, will lead to further advances in the
field of ALS and FTD research.
Each technique discussed in this review has advantages
and limitations, described above and in additional detail
elsewhere (Johnson et al., 2005; Parker et al., 2009; Neilson
et al., 2011; Megger et al., 2014; Arrington et al., 2017;
Lindemann et al., 2017; Martens and Vizcaino, 2017; Nadler
et al., 2017; Tholey and Becker, 2017). Importantly, issues of
reproducibility present in less frequently used and outdated
techniques such as surface-enhanced laser desorption/ionization
(SELDI) have been addressed by the introduction of newer
technologies. Whole proteome screening at high resolutions
has also replaced the need for “precision” techniques such
as two-dimensional polyacrylamide gel electrophoresis (2DPAGE) coupled to MS. The labeling of proximal proteins to
investigate PPIs using techniques such as BAR will allow for
more complex investigation that is not currently provided by
standard affinity chromatography methods. The implementation
of novel and high-throughput techniques in ALS/FTD can be
used to overcome current issues in variability between studies as
well as the low correlation of findings between differing studies.
Furthermore, the application of different techniques is contextdependent, and choice of technology must take into account both
biological and technical considerations. In addition, it is crucial
that both experimental approaches and data interpretation are
considered in study design.
In this review we have identified proteomics papers relevant
to ALS/FTD and presented them alongside discussion of current
technologies. The consistency amongst proteins identified strictly
depend on the disease type/model used, however, in ALS
research, TDP-43 as well as hnRNPs appear to reoccur (Ling
et al., 2013). An assessment as to whether these commonalities
are consistent has not been carried out as these would have to
account for differences in stress (oxidative/heat) as well as cell
type (neuron/cell-line/species).
In the context of ALS and FTD, greater focus should be given
to comparisons between new and existing proteomics datasets
as the growing number of studies are released using a variety
of available techniques. Further comparisons between ALS and
FTD datasets and those obtained from other neurodegenerative
diseases should also be performed, since there are likely to
be overlap in mechanisms which may be broadly involved in

neurodegeneration. This may also provide information on how
disease-specific alterations arise and why certain cell populations
or CNS regions are susceptible to different neurodegenerative
disease processes. For example, recent studies have applied
TMT to identify changes in various Alzheimer’s disease mice,
identifying hundreds of differentially expressed proteins (Kim
et al., 2018). Previously, these comparisons have also been used
for biomarker elucidation, attempting to highlight differences
between similar neurodegenerative diseases such as FTD and
Alzheimer’s disease (Teunissen et al., 2016).
Finally, it will also be informative to use these proteomic
techniques to more closely investigate biochemical changes
longitudinally in disease, particularly in studies of model systems
from which brain and spinal cord samples can be collected at
pre-defined time points. Strategies such as this are most likely to
reveal the earliest pathogenic changes in disease, which may be
most amenable to therapeutic intervention, but which may not
be identified by studies at later disease time points or by using
end-stage human tissue samples alone. The use of comparative
studies and recent advances in new technologies and labeling
techniques offers great hope for future understanding of ALS and
FTD, and development of clinical tests and therapeutics based
on these findings.
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